Zacks Investment Management Increases Position in Gilead Sciences INC (GILD)

January 22, 2018 - By Jan Rainey

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.10, from 0.93 in 2017Q2. It increased, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Selway Asset Management accumulated 22,050 shares. Bkd Wealth Advsr Ltd Limited Liability Company, Missouri-based fund reported 8,398 shares. Hartford Fincl Mngmt Incorporated, Connecticut-based fund reported 140 shares. Crestwood Advisors Group Llc, a Massachusetts-based fund reported 2,735 shares. Sun Life reported 12,613 shares. Marshall & Sullivan Wa has 22,322 shares. Mutual Of Omaha Retail Bank Wealth Mgmt reported 10,153 shares stake. Lingohr & Partner Asset Mngmt Gmbh has invested 0.8% in Gilead Sciences, Inc. (NASDAQ:GILD). Fukoku Mutual Life Insurance invested in 6,600 shares or 0.08% of the stock. Perkins Coie reported 0.03% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Wg Shaheen Associate Dba Whitney stated it has 0.94% in Gilead Sciences, Inc. (NASDAQ:GILD). Valueworks Ltd accumulated 71,908 shares. Sumitomo Mitsui Asset Mgmt Co Ltd has 0.13% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 99,873 shares. Knott David M invested in 0.36% or 10,420 shares. South State holds 0.1% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 10,829 shares.

Since August 1, 2017, it had 0 insider purchases, and 12 insider sales for $43.50 million activity. MARTIN JOHN C sold $6.09 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, August 31. $4.99 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by Meyers James R. Shares for $4.40 million were sold by Washington Robin L on Thursday, September 7.

Zacks Investment Management increased its stake in Gilead Sciences Inc (GILD) by 2191.09% based on its latest 2017Q3 regulatory filing with the SEC. Zacks Investment Management bought 574,658 shares as the company’s stock declined 8.05% while stock markets rallied. The institutional investor held 600,885 shares of the health care company at the end of 2017Q3, valued at $48.68M, up from 26,227 at the end of the previous reported quarter. Zacks Investment Management who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $105.78 billion market cap company. The stock decreased 0.23% or $0.19 during the last trading session, reaching $80.98. About 7.92 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 22, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Zacks Investment Management, which manages about $3.45 billion and $4.27 billion US Long portfolio, decreased its stake in Allison Transmission Hldgs I (NYSE:ALSN) by 386,573 shares to 95,412 shares, valued at $3.58 million in 2017Q3, according to the filing. It also reduced its holding in General Mtrs Co (NYSE:GM) by 92,316 shares in the quarter, leaving it with 151,222 shares, and cut its stake in Aes Corp (NYSE:AES).

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: which released: “On Investments: CVS, Gilead Sciences hit the Casualty List” on January 16, 2018, also with their article: “Is Gilead Sciences, Inc. a Buy in 2018?” published on January 17, 2018, published: “The case for Gilead Sciences” on January 21, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: and their article: “The Intrinsic Value Of Gilead Science” published on January 01, 2018 as well as‘s news article titled: “2018 Is Gilead’s Year” with publication date: January 16, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences has $137 highest and $7200 lowest target. $97.04’s average target is 19.83% above currents $80.98 stock price. Gilead Sciences had 112 analyst reports since July 29, 2015 according to SRatingsIntel. Bank of America upgraded Gilead Sciences, Inc. (NASDAQ:GILD) rating on Friday, January 15. Bank of America has “Neutral” rating and $107.0 target. The company was maintained on Monday, July 24 by J.P. Morgan. Credit Suisse maintained the stock with “Outperform” rating in Wednesday, September 14 report. The firm has “Buy” rating given on Thursday, September 28 by Mizuho. RBC Capital Markets maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Monday, October 3 with “Outperform” rating. On Thursday, August 31 the stock rating was upgraded by Argus Research to “Buy”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Hold” rating given on Monday, August 28 by Maxim Group. The rating was downgraded by Argus Research to “Hold” on Friday, July 29. Atlantic Securities initiated Gilead Sciences, Inc. (NASDAQ:GILD) rating on Friday, December 18. Atlantic Securities has “Neutral” rating and $111 target. The firm has “Buy” rating given on Wednesday, October 18 by Cowen & Co.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: